CoChat

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit *

Thong, K. Y., Jose, B., Sukumar, N., Cull, M. L., Mills, A. P., Sathyapalan, T., Shafiq, W., Rigby, A. S., Walton, C., Ryder, R. E. J., on behalf of the ABCD nationwide exenatide audit contributors · 2011 · Diabetes, Obesity and Metabolism
Cited by 96

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aim: To assess the extent, safety, efficacy and tolerability of reported off‐licence exenatide use through a nationwide audit. Methods: The Association of British Clinical Diabetologists hosted a password‐protected, online collection of anonymized data of exenatide use in real clinical practice. Three hundred and fifteen contributors from 126 centres across UK provided data on 6717 patients. HbA1c and weight changes, exenatide discontinuation, adverse events and treatment satisfaction were compared between non‐insulin and insulin‐treated patients. Results: Four thousand eight hundred and fifty‐seven patients had baseline and follow‐up treatment status with mean (±s.d.) baseline HbA1c 9.45 ± 1.69% and BMI 40.0 ± 8.2 kg/m 2 . Of the 4857 patients, 1921 (39.6%) used exenatide with insulin. Comparing patients who continued insulin with exenatide with non‐insulin‐treated patients, mean (±s.e.) latest HbA1c and weight reduction (median 26 weeks) were 0.51 ± 0.06 versus 0.94 ± 0.04% (p < 0.001) and 5.8 ± 0.2 versus 5.5 ± 0.1 kg (p = 0.278). Insulin‐treated patients had higher rates of exenatide discontinuation (31.0 vs. 13.9%, p < 0.001), hypoglycaemia (8.9 vs. 6.1%, p < 0.001), gastrointestinal side effects (28.4 vs. 25.0%, p = 0.008) and treatment dissatisfaction (20.8 vs. 5.7%, p < 0.001). However, 34.2% of the patients continuing insulin still achieved HbA1c reduction ≥1%. There was significant insulin discontinuation, dose reduction and greater sulphonylurea discontinuation among insulin‐treated patients. Conclusions: Addition of exenatide to obese, insulin‐treated patients can improve glycaemia and weight. Adverse events were statistically but probably not clinically significantly higher, but combination treatment was less well tolerated. Overall, exenatide was less effective in lowering HbA1c among insulin‐treated patients, although significant number of insulin‐treated patients still achieved significant HbA1c, weight and insulin reductions. Further research into identifying obese, insulin‐treated patients who will tolerate and benefit from exenatide treatment is urgently needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01393.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 96

Metadata

Authors
Thong, K. Y., Jose, B., Sukumar, N., Cull, M. L., Mills, A. P., Sathyapalan, T., Shafiq, W., Rigby, A. S., Walton, C., Ryder, R. E. J., & contributors, O. B. O. T. A. N. E. A.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-06-21
Volume
13
Issue
8
Pages
703-710
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2166714657
Cited by
96
References
6
FWCI
15.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit *. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01393.x
The paper
Thong, K. Y., Jose, B., Sukumar, N., Cull, M. L., Mills, A. P., Sathyapalan, T., Shafiq, W., Rigby, A. S., Walton, C., Ryder, R. E. J., & contributors, O. B. O. T. A. N. E. A. (2011). Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit *. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01393.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.